Review



ffpe microarray test  (Agendia BV)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Agendia BV ffpe microarray test
    MammaPrint (MP) <t>microarray</t> indices assessed at Agendia Amsterdam central laboratory in comparison to MP NGS indices at the beta sites. The comparison shows equivalence between the two technologies (Pearson's r = 0.96). The x-axis reports the MP microarray index, the y-axis reports the MP NGS index. Each dot represents a single breast cancer sample for which total RNA underwent microarray and NGS laboratory processing and analysis. The blue dots represent the discordant cases with indices close to the classification threshold.
    Ffpe Microarray Test, supplied by Agendia BV, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ffpe microarray test/product/Agendia BV
    Average 90 stars, based on 1 article reviews
    ffpe microarray test - by Bioz Stars, 2026-04
    90/100 stars

    Images

    1) Product Images from "Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and BluePrint® Kit at University Hospitals Leuven and Curie Institute Paris"

    Article Title: Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and BluePrint® Kit at University Hospitals Leuven and Curie Institute Paris

    Journal: Translational Oncology

    doi: 10.1016/j.tranon.2019.08.008

    MammaPrint (MP) microarray indices assessed at Agendia Amsterdam central laboratory in comparison to MP NGS indices at the beta sites. The comparison shows equivalence between the two technologies (Pearson's r = 0.96). The x-axis reports the MP microarray index, the y-axis reports the MP NGS index. Each dot represents a single breast cancer sample for which total RNA underwent microarray and NGS laboratory processing and analysis. The blue dots represent the discordant cases with indices close to the classification threshold.
    Figure Legend Snippet: MammaPrint (MP) microarray indices assessed at Agendia Amsterdam central laboratory in comparison to MP NGS indices at the beta sites. The comparison shows equivalence between the two technologies (Pearson's r = 0.96). The x-axis reports the MP microarray index, the y-axis reports the MP NGS index. Each dot represents a single breast cancer sample for which total RNA underwent microarray and NGS laboratory processing and analysis. The blue dots represent the discordant cases with indices close to the classification threshold.

    Techniques Used: Microarray, Comparison

    Comparison of test outcomes from MammaPrint (High/Low Risk) between microarray assessed at Agendia Amsterdam central laboratory and NGS assessed at the beta sites. These results show a Negative Predictive Agreement (Low Risk) of 93.8% (60/64, 95% CI: 85.0–97.5), a Positive Predictive Agreement (High Risk) of 88.3% (53/60, 95% CI: 77.8–94.2), a concordance of 91.1% and a Cohen's kappa of 0.82.
    Figure Legend Snippet: Comparison of test outcomes from MammaPrint (High/Low Risk) between microarray assessed at Agendia Amsterdam central laboratory and NGS assessed at the beta sites. These results show a Negative Predictive Agreement (Low Risk) of 93.8% (60/64, 95% CI: 85.0–97.5), a Positive Predictive Agreement (High Risk) of 88.3% (53/60, 95% CI: 77.8–94.2), a concordance of 91.1% and a Cohen's kappa of 0.82.

    Techniques Used: Comparison, Microarray

    Comparison of molecular subtyping using MP and BP tests (Luminal A for Low Risk MP and Luminal B for High Risk) between NGS Beta Site and IHC according to Prat et al. (n = 124) ( A ), between NGS Beta Site and IHC according to Maisonneuve et al. (n = 124) ( B ), between NGS Beta Site and microarray Agendia (n = 124) ( C ), and between NGS Beta Site and NGS Agendia (n = 114 <xref ref-type= ∗ ) ( D ). These results show a concordance of 71.8% (89/124) ( A ), 76.6% (95/124) ( B ), 89.5% (111/124) ( C ) and 93.9% (107/114) ( D )." title="... ( B ), between NGS Beta Site and microarray Agendia (n = 124) ( C ..." property="contentUrl" width="100%" height="100%"/>
    Figure Legend Snippet: Comparison of molecular subtyping using MP and BP tests (Luminal A for Low Risk MP and Luminal B for High Risk) between NGS Beta Site and IHC according to Prat et al. (n = 124) ( A ), between NGS Beta Site and IHC according to Maisonneuve et al. (n = 124) ( B ), between NGS Beta Site and microarray Agendia (n = 124) ( C ), and between NGS Beta Site and NGS Agendia (n = 114 ∗ ) ( D ). These results show a concordance of 71.8% (89/124) ( A ), 76.6% (95/124) ( B ), 89.5% (111/124) ( C ) and 93.9% (107/114) ( D ).

    Techniques Used: Comparison, Microarray

    MammaPrint (MP) NGS indices assessed at Agendia Amsterdam central laboratory in comparison to MP NGS at the beta sites. The comparison shows equivalence between MP NGS performed at Agendia (x-axis) and MP NGS at the beta sites (y-axis) (Pearson's r = 0.96) (n = 114). Each dot represents a single breast cancer sample for which total RNA underwent NGS or microarray laboratory processing and analysis. Out of the 124 samples processed on NGS, 10 samples lacked NGS results at Agendia. The blue dots represent the discordant cases with indices close to the classification threshold.
    Figure Legend Snippet: MammaPrint (MP) NGS indices assessed at Agendia Amsterdam central laboratory in comparison to MP NGS at the beta sites. The comparison shows equivalence between MP NGS performed at Agendia (x-axis) and MP NGS at the beta sites (y-axis) (Pearson's r = 0.96) (n = 114). Each dot represents a single breast cancer sample for which total RNA underwent NGS or microarray laboratory processing and analysis. Out of the 124 samples processed on NGS, 10 samples lacked NGS results at Agendia. The blue dots represent the discordant cases with indices close to the classification threshold.

    Techniques Used: Comparison, Microarray



    Similar Products

    ffpe microarray test  (Agendia BV)
    90
    Agendia BV ffpe microarray test
    MammaPrint (MP) <t>microarray</t> indices assessed at Agendia Amsterdam central laboratory in comparison to MP NGS indices at the beta sites. The comparison shows equivalence between the two technologies (Pearson's r = 0.96). The x-axis reports the MP microarray index, the y-axis reports the MP NGS index. Each dot represents a single breast cancer sample for which total RNA underwent microarray and NGS laboratory processing and analysis. The blue dots represent the discordant cases with indices close to the classification threshold.
    Ffpe Microarray Test, supplied by Agendia BV, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ffpe microarray test/product/Agendia BV
    Average 90 stars, based on 1 article reviews
    ffpe microarray test - by Bioz Stars, 2026-04
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    MammaPrint (MP) microarray indices assessed at Agendia Amsterdam central laboratory in comparison to MP NGS indices at the beta sites. The comparison shows equivalence between the two technologies (Pearson's r = 0.96). The x-axis reports the MP microarray index, the y-axis reports the MP NGS index. Each dot represents a single breast cancer sample for which total RNA underwent microarray and NGS laboratory processing and analysis. The blue dots represent the discordant cases with indices close to the classification threshold.

    Journal: Translational Oncology

    Article Title: Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and BluePrint® Kit at University Hospitals Leuven and Curie Institute Paris

    doi: 10.1016/j.tranon.2019.08.008

    Figure Lengend Snippet: MammaPrint (MP) microarray indices assessed at Agendia Amsterdam central laboratory in comparison to MP NGS indices at the beta sites. The comparison shows equivalence between the two technologies (Pearson's r = 0.96). The x-axis reports the MP microarray index, the y-axis reports the MP NGS index. Each dot represents a single breast cancer sample for which total RNA underwent microarray and NGS laboratory processing and analysis. The blue dots represent the discordant cases with indices close to the classification threshold.

    Article Snippet: The current MP and BP gold standard FFPE microarray test was recently successfully translated to a targeted RNA NGS based test at Agendia laboratories .

    Techniques: Microarray, Comparison

    Comparison of test outcomes from MammaPrint (High/Low Risk) between microarray assessed at Agendia Amsterdam central laboratory and NGS assessed at the beta sites. These results show a Negative Predictive Agreement (Low Risk) of 93.8% (60/64, 95% CI: 85.0–97.5), a Positive Predictive Agreement (High Risk) of 88.3% (53/60, 95% CI: 77.8–94.2), a concordance of 91.1% and a Cohen's kappa of 0.82.

    Journal: Translational Oncology

    Article Title: Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and BluePrint® Kit at University Hospitals Leuven and Curie Institute Paris

    doi: 10.1016/j.tranon.2019.08.008

    Figure Lengend Snippet: Comparison of test outcomes from MammaPrint (High/Low Risk) between microarray assessed at Agendia Amsterdam central laboratory and NGS assessed at the beta sites. These results show a Negative Predictive Agreement (Low Risk) of 93.8% (60/64, 95% CI: 85.0–97.5), a Positive Predictive Agreement (High Risk) of 88.3% (53/60, 95% CI: 77.8–94.2), a concordance of 91.1% and a Cohen's kappa of 0.82.

    Article Snippet: The current MP and BP gold standard FFPE microarray test was recently successfully translated to a targeted RNA NGS based test at Agendia laboratories .

    Techniques: Comparison, Microarray

    Comparison of molecular subtyping using MP and BP tests (Luminal A for Low Risk MP and Luminal B for High Risk) between NGS Beta Site and IHC according to Prat et al. (n = 124) ( A ), between NGS Beta Site and IHC according to Maisonneuve et al. (n = 124) ( B ), between NGS Beta Site and microarray Agendia (n = 124) ( C ), and between NGS Beta Site and NGS Agendia (n = 114 <xref ref-type= ∗ ) ( D ). These results show a concordance of 71.8% (89/124) ( A ), 76.6% (95/124) ( B ), 89.5% (111/124) ( C ) and 93.9% (107/114) ( D )." width="100%" height="100%">

    Journal: Translational Oncology

    Article Title: Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and BluePrint® Kit at University Hospitals Leuven and Curie Institute Paris

    doi: 10.1016/j.tranon.2019.08.008

    Figure Lengend Snippet: Comparison of molecular subtyping using MP and BP tests (Luminal A for Low Risk MP and Luminal B for High Risk) between NGS Beta Site and IHC according to Prat et al. (n = 124) ( A ), between NGS Beta Site and IHC according to Maisonneuve et al. (n = 124) ( B ), between NGS Beta Site and microarray Agendia (n = 124) ( C ), and between NGS Beta Site and NGS Agendia (n = 114 ∗ ) ( D ). These results show a concordance of 71.8% (89/124) ( A ), 76.6% (95/124) ( B ), 89.5% (111/124) ( C ) and 93.9% (107/114) ( D ).

    Article Snippet: The current MP and BP gold standard FFPE microarray test was recently successfully translated to a targeted RNA NGS based test at Agendia laboratories .

    Techniques: Comparison, Microarray

    MammaPrint (MP) NGS indices assessed at Agendia Amsterdam central laboratory in comparison to MP NGS at the beta sites. The comparison shows equivalence between MP NGS performed at Agendia (x-axis) and MP NGS at the beta sites (y-axis) (Pearson's r = 0.96) (n = 114). Each dot represents a single breast cancer sample for which total RNA underwent NGS or microarray laboratory processing and analysis. Out of the 124 samples processed on NGS, 10 samples lacked NGS results at Agendia. The blue dots represent the discordant cases with indices close to the classification threshold.

    Journal: Translational Oncology

    Article Title: Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and BluePrint® Kit at University Hospitals Leuven and Curie Institute Paris

    doi: 10.1016/j.tranon.2019.08.008

    Figure Lengend Snippet: MammaPrint (MP) NGS indices assessed at Agendia Amsterdam central laboratory in comparison to MP NGS at the beta sites. The comparison shows equivalence between MP NGS performed at Agendia (x-axis) and MP NGS at the beta sites (y-axis) (Pearson's r = 0.96) (n = 114). Each dot represents a single breast cancer sample for which total RNA underwent NGS or microarray laboratory processing and analysis. Out of the 124 samples processed on NGS, 10 samples lacked NGS results at Agendia. The blue dots represent the discordant cases with indices close to the classification threshold.

    Article Snippet: The current MP and BP gold standard FFPE microarray test was recently successfully translated to a targeted RNA NGS based test at Agendia laboratories .

    Techniques: Comparison, Microarray